Emergex is an Oxford-based company using innovative new technology to create synthetic vaccines that are ideally suited to low resource environments. These products will be used to create a clinical grade international vaccine repository that will act as a first line of defence against existing and newly emerging infectious outbreaks. Emergex is initially prioritising a multitarget vaccine for Zika, Dengue and Chikungunya, a multi-strain vaccine against Ebola/Marburg and a universal flu vaccine.

Emergex was formed with the vision of tackling the global threat of infectious disease by providing affordable, effective and practical vaccines. Outbreaks of infectious disease, such as Zika and Ebola, disproportionately affect people in developing countries. They often occur rapidly and unexpectedly, where a viable vaccine, the gold standard of defence against viral disease, is not available or effective.

Using a combination of two patent protected technologies, Emergex can develop 100% synthetic vaccines that can be developed and manufactured at a fraction of the time and cost of traditional vaccines. These vaccines are applicable to a wide range of disease indications and have practical benefits such as being temperature stable and suited to skin patch immunisation, making them ideally suited to the low resource environments where they are most needed. They will be used to create a clinical grade international vaccine repository . Emergex will offer its customers ’’œ governments, NGOs and multi-lateral organisations access to this repository. This will enable customers to be prepared for epidemics through keeping a reserved stock of readily available, effective vaccines and subscribing to on-demand vaccine production, allowing them to rapidly offer vaccination against the disease in question to affected populations.

Emergex Impact Report